BioSpace News Archive

The latest market analysis report published by Reports and Data, titled ‘Global Alopecia Market – Forecast to 2030,’ thoroughly examines the Alopecia industry to provide essential data & information for the targeted readers.

Arcutis Biotherapeutics, Inc. reported the grant of an aggregate of 32,300 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 85,800 shares of Arcutis’ common stock to nine newly hired employees.

Atreca, Inc. today announced two poster presentations at the SITC 2022 Annual Meeting, being held November 8-12 in Boston, Massachusetts.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, October 6, 2022, at 8:00 a.m. (ET) to report top-line results from Part 1 of the Phase 3 GUARD Trial of ADX-2191 (methotrexate injection, United States Pharmacopeia) for intravitreal administration in patients with proliferative vitreoretinopathy (PVR), a rare, sight-threatening ocular disease with no approved therapy.

Colossal Biosciences, a breakthrough genetic engineering and de-extinction company, accelerates efforts to end elephant extinction on Earth.

InterVenn Biosciences announced that its co-founder Carolyn Bertozzi, Ph.D., has been awarded the 2022 Nobel Prize in chemistry.

Science 37 ® Holdings, Inc. (Nasdaq: SNCE), the Agile Clinical Trial Operating System™, today announced the appointment of seasoned industry and technology executive Paul von Autenried to its Board of Directors.

Diabetes is one of the most prevalent chronic diseases in Canada with over 3 million people with diabetes in the country and 200,000 new cases diagnosed every year.

Navidea Biopharmaceuticals, Inc. today announced that results from the Company’s ongoing preclinical studies evaluating targeted immunotherapy for cancer based on the Manocept platform have been accepted for presentation at the 37th Annual Meeting of the Society for Immunotherapy of Cancer.

LadRx Corporation announced it is changing its OTCQB ticker symbol from CYTR to LADX effective Thursday, October 6, 2022.